In contrast, Gadgeel et al. reported a median PFS of 8.3 months in EGFR-mutant NSCLC patients with platinum/pemetrexed/pembrolizumab [10], out-performing historical controls. This evidence concerns the gene EGFR and non-small cell lung carcinoma.